aTyr Pharma Awarded Two Patents from USPTO to Support Development of New Therapeutics Based on Physiocrine Biology
August 14, 2013aTyr Pharma Awarded Two Patents from USPTO to Support Development of New Therapeutics Based on Physiocrine Biology
More »
Celator® Pharmaceuticals Announces Start Of Clinical Study In Patients With Untreated Myelodysplastic Syndrome (MDS) Or Acute Myeloid Leukemia At High Risk Of Treatment-Related Mortality
August 13, 2013The potential benefit of disease-directed therapy is well established. Celator’s clinical study in patients with high risk of treatment-related mortality is designed to find efficacious treatments in medically unfit patients with AML or high-risk MDS.
More »
Dicerna Secures $60 Million in Oversubscribed Series C Financing
August 1, 2013Proceeds from the financing will be used to advance two or more programs into the clinic and to progress other preclinical programs. The company also plans to use the proceeds to continue to develop innovative drug delivery systems.
More »